FeesSafety
Pluang+

Uniswap Labs supports tokenized US stock venues under SEC's new five-year conditional relief.

Market News
11 Nov 2026, 22:32 WIB
Tokenpost
View Source
Bullish
Uniswap Labs supports tokenized US stock venues under SEC's new five-year conditional relief.

Uniswap Labs is providing tools and guidance to operators of tokenized U.S. stock trading venues under the SEC's five-year conditional relief issued on September 17. This relief applies to venues trading certain National Market System stocks via permissioned automated market maker pools, allowing independent operators to manage compliance and operations. Uniswap v4 offers features like access controls and trading halts to support these venues, which have collectively processed over $20 billion in stock-trading volume. The framework expires in 2031 and does not cover all tokenized-stock platforms, but it marks a significant step in regulated tokenized stock trading.

Uniswap Labs' new tools for tokenized stock venues come as a backdrop to current crypto market activity. For readers following major cryptocurrencies on Pluang, here is the market snapshot as of Nov 12, 2026 03:21 WIB: out of 50 major cryptocurrencies, 32 rose and 17 fell. Notable movers include FIL at Rp13.938 with a 3.71% gain and 100% buy order activity, XLM at Rp2.697 up 3.69%, and VET at Rp96 with a 2.73% increase but 96% sell order activity.

More News

Global beverage market to reach $2.78T by 2032, driven by nonalcoholic drinks and convenience trends.

Global beverage market to reach $2.78T by 2032, driven by nonalcoholic drinks and convenience trends.

The global beverage market is projected to grow from $2.03 trillion in 2026 to $2.78 trillion by 2032, at a CAGR of 5.35%. Growth is fueled by rising demand for nonalcoholic and functional beverages, convenience packaging, and premium products for sp...

Market News
Bullish
2 hours ago
Over 200 GLP-1 and incretin therapies in development are reshaping diabetes and obesity treatment landscapes.

Over 200 GLP-1 and incretin therapies in development are reshaping diabetes and obesity treatment landscapes.

DelveInsight's 2026 report reveals more than 200 GLP-1 receptor agonists and incretin-based therapies are in development by over 180 companies, targeting conditions like type 2 diabetes, obesity, and related metabolic disorders. Key players such as E...

Bullish
2 hours ago
Nvidia remains attractively valued at 11x FY 2028 earnings despite short-term risks from China and AI cycles.

Nvidia remains attractively valued at 11x FY 2028 earnings despite short-term risks from China and AI cycles.

Nvidia Corporation is currently trading at a reasonable valuation of 11 times its projected earnings for fiscal year 2028, reflecting strong financial and operational growth since mid-2025. While regulatory and geopolitical risks, especially related ...

Analyst Insights
Bullish
5 hours ago
Bitcoin risks first-ever back-to-back yearly losses, down 16.5% in 2026 after a slight 2025 drop.

Bitcoin risks first-ever back-to-back yearly losses, down 16.5% in 2026 after a slight 2025 drop.

Bitcoin is on track to record consecutive yearly losses for the first time in its 18-year history, with a 6.34% drop in 2025 followed by a 16.5% decline so far in 2026. Prominent critic Peter Schiff highlighted this unusual trend, warning it could le...

Market News
Bearish
5 hours ago
Tron Inc. posts $14.9M Q3 net income, up 22%, with digital assets at $257.8M and growing TRX treasury.

Tron Inc. posts $14.9M Q3 net income, up 22%, with digital assets at $257.8M and growing TRX treasury.

Tron Inc. reported a net income of $14.9 million for Q3 2026, marking a 22% increase from $12.2 million a year earlier. For the first nine months of 2026, net income surged about 203% to $39.4 million. The company held $257.8 million in digital-asset...

Protocol Fundamentals
Bullish
5 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App